Abstract | BACKGROUND: The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients. METHODS: RESULTS: Of 3,278 patients that started abacavir, 2,101 (64.1%) discontinued. Of these, 167 (5.1%) discontinued abacavir within 3 months due to HSR with an incidence of 22.1 (95% confidence interval [CI] 18.7-25.4) per 100 person-years of follow-up. After adjustment for gender, prior AIDS, hepatitis C serostatus, baseline CD4+ T-cell count, region and calendar time, HSR incidence was significantly higher in those starting abacavir in a first-line regimen compared with second-line (incidence rate ratio [ IRR] 2.04 [95% CI 1.24-3.38]; P=0.005). There was no significant difference between regions. HSR incidence from 2005 onwards was significantly lower compared with 1999-2000 ( IRR 0.54 [95% CI 0.32-0.92]; P=0.024). There was a lower observed incidence in patients starting abacavir/lamivudine compared with other formulations ( IRR 0.33 [95% CI 0.13-0.88]; P=0.027), however, available data were limited. CONCLUSIONS: Incidence of abacavir-related HSR is higher in patients starting abacavir in first-line therapy, which could indicate increased over-diagnosis. HSR incidence has decreased in recent years, which might reflect the wider availability of genetic screening and improved awareness of symptoms. There were no reported deaths due to abacavir HSR.
|
Authors | Wendy P Bannister, Nina Friis-Møller, Amanda Mocroft, Jean-Paul Viard, Jan van Lunzen, Ole Kirk, Panagiotis Gargalianos, Dénes Bánhegyi, Antonio Chiesi, Jens D Lundgren, EuroSIDA Study Group |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 13
Issue 5
Pg. 687-96
( 2008)
ISSN: 1359-6535 [Print] England |
PMID | 18771052
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Dideoxynucleosides
- Reverse Transcriptase Inhibitors
- Lamivudine
- Zidovudine
- abacavir
|
Topics |
- Adult
- Anti-HIV Agents
(administration & dosage, adverse effects, therapeutic use)
- Cohort Studies
- Dideoxynucleosides
(administration & dosage, adverse effects, therapeutic use)
- Drug Administration Schedule
- Drug Hypersensitivity
(epidemiology, etiology, mortality)
- Drug Therapy, Combination
- Europe
- Female
- HIV Infections
(drug therapy, mortality, virology)
- HIV-1
(drug effects)
- Humans
- Incidence
- Lamivudine
(administration & dosage)
- Male
- Middle Aged
- Poisson Distribution
- Reverse Transcriptase Inhibitors
(administration & dosage, adverse effects)
- Treatment Outcome
- Zidovudine
(administration & dosage)
|